V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240008322 | 240005100 | 1.85 | null | Curative (C) | 2017-09-07 | 2017-09-16 | IBRUTINIB | N | N | 240007970 | IBRUTINIB |
| 240008323 | 240005101 | 1.82 | 67.6 | null | 2019-04-07 | 2019-04-07 | FLAG + Idarubicin | null | null | 240007996 | Y-90 |
| 240008324 | 240005101 | 1.74 | 61 | Curative (C) | 2019-03-11 | 2019-03-11 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | N | N | 240007996 | BEVACIZUMAB + CISPLATIN + PACLITAXEL |
| 240008325 | 240005102 | 1.84 | 112 | Palliative (P) | 2016-08-15 | 2016-08-30 | FCR | N | N | 240008094 | FCR |
| 240008326 | 240005102 | 1.86 | null | Palliative (P) | 2015-02-22 | 2015-03-07 | DA-EPOCH-R | N | N | 240008094 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 240008327 | 240005102 | 1.71 | 106 | Disease modification (D) | 2015-01-16 | 2015-02-08 | AML17 TRIAL | 2 | N | 240008094 | AML17 TRIAL |
| 240008328 | 240005103 | null | 89 | Palliative (P) | 2016-11-17 | 2017-01-31 | Cisplatin + Etoposide po&iv 3 day | N | Y | 240008205 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008329 | 240005104 | null | 100 | Neo-adjuvant (N) | 2013-12-09 | 2015-11-13 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | Y | Y | 240008242 | CISPLATIN + TOPOTECAN |
| 240008330 | 240005104 | 1.78 | 60 | Palliative (P) | 2017-10-01 | 2017-11-05 | Capecitabine 35days + RT | 02 | N | 240008242 | METHOTREXATE INTRATHECAL |
| 240008331 | 240005105 | 1.6 | 63.4 | Curative (C) | 2014-06-16 | 2014-06-17 | MPV (cycle 1-4) | 02 | N | 240008302 | mEOC TRIAL |
| 240008332 | 240005105 | 1.59 | 64.7 | null | 2015-10-21 | 2015-11-04 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | N | N | 240008302 | CISPLATIN + TOPOTECAN |
| 240008333 | 240005105 | 1.83 | 55 | Curative (C) | 2017-11-11 | 2017-11-14 | Carboplatin + Pemetrexed | N | N | 240008302 | PEMBROLIZUMAB |
| 240008334 | 240005105 | 1.6 | 120.4 | Palliative (P) | 2013-10-24 | 2013-11-13 | Cyclophosphamide oral | N | N | 240008302 | AML16 TRIAL |
| 240008335 | 240015663 | 1.6 | 41.7 | Palliative (P) | 2018-01-14 | 2018-03-04 | FLAG + Idarubicin | 02 | N | 240008385 | CISPLATIN + VINORELBINE |
| 240008336 | 240015663 | 1.63 | 65.9 | Palliative (P) | 2016-09-28 | 2016-10-19 | Cisplatin + Etoposide (3 day) | N | N | 240008385 | CARBOPLATIN + DOXORUBICIN |
| 240008337 | 240015663 | 1.77 | 89.5 | Palliative (P) | 2017-05-24 | 2017-05-28 | CHLORAMBUCIL + OBINUTUZUMAB | N | N | 240008385 | TRIPLE INTRATHECAL |
| 240008338 | 240005106 | null | 73 | Palliative (P) | 2014-12-19 | 2014-12-19 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | null | N | 240008453 | RCEOP |
| 240008339 | 240010824 | 1.52 | null | Disease modification (D) | 2016-02-26 | 2016-02-27 | CVP | null | N | 240008463 | CAV |
| 240008340 | 240005107 | null | 87 | Palliative (P) | null | 2015-02-24 | ATG + Busulfan + Fludarabine | null | null | 240008494 | MIDAC |
| 240008341 | 240010825 | 1.53 | 72.6 | Curative (C) | 2015-03-10 | 2015-03-10 | GEMCITABINE | N | N | 240008503 | R CODOX-M/ R IVAC |
| 240008342 | 240005108 | null | 44.9 | Palliative (P) | 2018-04-14 | 2018-04-22 | Cisplatin + Topotecan | null | null | 240008596 | BEVACIZUMAB |
| 240008343 | 240010826 | 1.57 | 78.7 | Not known (9) | 2015-07-13 | 2015-07-15 | FCR Oral - Cycle 2 onwards | N | N | 240008624 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB |
| 240008344 | 240005109 | 1.66 | 68.4 | null | 2014-10-26 | 2014-10-30 | Bevacizumab+Carbo+Gemcitabine | 2 | N | 240008658 | SUNITINIB |
| 240008345 | 240005110 | 1.68 | 79.2 | Palliative (P) | 2015-07-21 | 2015-07-21 | CVP | 2 | null | 240008683 | AML17 TRIAL |
| 240008346 | 240005111 | null | 76 | Disease modification (D) | 2014-12-14 | 2014-12-17 | Gemcitabine + Capecitabine | 02 | N | 240008724 | BLEOMYCIN + CISPLATIN + MTOMYCIN |
| 240008347 | 240005112 | null | 52 | Adjuvant (A) | 2015-03-16 | 2015-03-18 | Enzalutamide | N | null | 240008732 | CHOP-R + CYTARABINE HIGH DOSE |
| 240008348 | 240005112 | 1.59 | 55 | Palliative (P) | 2015-07-02 | 2015-07-04 | Capecitabine (21days) + Carboplatin | 02 | N | 240008732 | PARAGON TRIAL |
| 240008349 | 240005113 | null | 36.55 | Curative (C) | 2013-11-01 | 2013-11-03 | ETOPOSIDE | N | null | 240008851 | mEOC TRIAL |
| 240008350 | 240005113 | 1.66 | null | null | 2015-05-12 | 2015-05-20 | Cisplatin + Etoposide (3 day) | null | null | 240008851 | CYTARABINE HIGH DOSE |
| 240008351 | 240005114 | 1.75 | 98.9 | Curative (C) | 2015-10-15 | 2015-10-25 | CISPLATIN + GEMCITABINE | 2 | N | 240008940 | CYTARABINE INTRATHECAL |
| 240008352 | 240005114 | -1 | 69 | Curative (C) | 2016-01-16 | 2016-02-02 | Methotrexate intrathecal | N | null | 240008940 | CLADRIBINE |
| 240008353 | 240005114 | 1.58 | 65.8 | Palliative (P) | 2017-09-16 | 2017-09-18 | NORDIC | N | N | 240008940 | PMITCEBO-R |
| 240008354 | 240014967 | 1.59 | 59 | Curative (C) | 2015-11-22 | 2015-11-22 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINBLASTINE | Y | N | 240009059 | CISPLATIN + VINORELBINE |
| 240008355 | 240005115 | 1.79 | 73.8 | Palliative (P) | 2015-03-30 | 2015-04-10 | VAC | 02 | N | 240009075 | FLAG |
| 240008356 | 240010830 | 1.59 | null | Disease modification (D) | null | 2017-08-15 | AML 18 Pilot Trial | N | null | 240009150 | EOX |
| 240008357 | 240010830 | 1.55 | 0 | Curative (C) | 2015-10-21 | 2015-10-21 | Bevacizumab 15mg/kg | N | N | 240009150 | FCR |
| 240008358 | 240005116 | 1.58 | 59.6 | Curative (C) | 2015-06-09 | 2015-06-15 | CYCLO + RITUXIMAB + VINCRISTINE | 02 | N | 240009199 | MITOXANTRONE |
| 240008359 | 240005117 | 1.54 | null | Neo-adjuvant (N) | 2016-11-25 | 2016-12-10 | CHLVPP | null | N | 240009211 | TEMOZOLOMIDE |
| 240008360 | 240005118 | 1.68 | 67.4 | Neo-adjuvant (N) | 2015-10-21 | 2015-10-21 | Methotrexate intrathecal | N | N | 240009230 | CISPLATIN + TOPOTECAN |
| 240008361 | 240005118 | 1.55 | 107.5 | Curative (C) | 2018-05-03 | 2018-06-07 | Cisplatin + Etoposide (3 day) | N | N | 240009230 | CARBOPLATIN + RT |
| 240008362 | 240005118 | 1.63 | 50 | Adjuvant (A) | 2018-06-26 | 2018-06-26 | Oxaliplatin + Modified de Gramont | N | N | 240009230 | BORTEZOMIB + THALIDOMIDE |
| 240008363 | 240005119 | 1.63 | 89.9 | Curative (C) | 2014-04-09 | 2014-05-14 | DA-EPOCH-R | N | N | 240009272 | NILOTINIB |
| 240008364 | 240005120 | 1.48 | 69 | Palliative (P) | 2017-02-04 | 2017-02-04 | PMitCEBO-R | null | N | 240009292 | FLUDARABINE |
| 240008365 | 240005120 | null | 74.9 | null | 2015-09-26 | 2015-10-03 | Docetaxel 100mg/m2 (21 day) | N | null | 240009292 | CYCLOPHOSPHAMIDE |
| 240008366 | 240005121 | 1.63 | 56.7 | Curative (C) | 2017-01-28 | 2017-02-08 | Cisplatin + Topotecan | 2 | N | 240009299 | BEVACIZUMAB |
| 240008367 | 240005121 | 1.61 | null | Palliative (P) | 2018-03-20 | 2018-03-27 | Cisplatin +Fluorouracil (2 wk) | 02 | N | 240009299 | CISPLATIN + TOPOTECAN |
| 240008368 | 240013608 | 1.65 | 41.1 | null | 2018-09-21 | 2018-10-10 | PEMBROLIZUMAB | 02 | null | 240009348 | CVP |
| 240008369 | 240005122 | 1.53 | 66 | Palliative (P) | 2015-01-09 | 2015-01-13 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 2 | N | 240009374 | ABVD |
| 240008370 | 240005122 | null | 82.2 | null | 2018-02-20 | 2018-02-28 | Cytarabine Low Dose | Y | N | 240009374 | AML19 TRIAL |
| 240008371 | 240005123 | 1.85 | 63 | Curative (C) | 2013-03-12 | 2013-03-14 | Methotrexate intrathecal | N | N | 240009574 | NORDIC |